D Williamson, M Chawla, R Marks. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh： See more » Acetylmuramyl-Alanyl-Isoglutamine/administration & dosageAcetylmuramyl-Alanyl-Isoglutamine/adverse effectsAcetylmuramyl-Alanyl-Isoglutamine/analogs & derivativesAcetylmuramyl-Alanyl-Isoglutamine/therapeutic useAdjuvants, Immunologic/administration & dosageAdjuvants, Immunologic/adverse effectsAdjuvants, Immunologic/therapeutic useAdministration, OralFollow-Up StudiesHumansPain/etiologyPruritus/therapyPsoriasis/classificationPsoriasis/pathologyPsoriasis/therapySeverity of Illness IndexT-Lymphocyte Subsets/pathologyVomiting/etiology
Substances： See more » Adjuvants, ImmunologicAcetylmuramyl-Alanyl-Isoglutamineglucosaminylmuramyl-2-alanine-D-isoglutamine
Year: 1998 PMID： 9716065 DOI： 10.1016/S0140-6736(05)79253-9
Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321